Evaluation of oxaliplatin and tigio combination therapy in locally advanced gastric cancer

Table 1 Comparison of clinical data between the two groups

Index	Study group (n = 45)	Control group (n = 45)	χ2/t	P value
Sex			0.044	0.832
Male	25	24
Female	20	21
Age (yr)	48.80 ± 9.50	49.50 ± 9.80	0.639	0.524
BMI (kg/m2)	23.50 ± 3.12	24.01 ± 2.85	0.796	0.427
Complications (n)			0.795	0.672
Diabetes	4	5
Hypertension	18	14
Hyperlipidemia	9	11
Arrhythmia	2	1
Smoking history (n)			0.189	0.664
Yes	16	18
No	29	27
Drinking history (n)			0.179	0.673
Yes	20	22
No	25	23

BMI: Body mass index.

Table 2 Analysis of short-term efficacy of patients between two groups

Index	Study group (n = 45)		Control group (n = 45)		χ2	P value
	n	%	n	%
CR	11	24.44	9	20.00
PR	25	55.56	17	37.78
SD	6	13.33	12	26.67
PD	3	6.67	7	15.56
ORR (CR + PR)	36	80.00	26	57.78	11.519	0.011
DCR (CR + PR + SD)	42	93.33	38	84.44	4.215	0.016

CR: Complete response; PR: Partial response; SD: Stable disease; PD: Progressive disease; ORR: Overall response Rate; DCR: Disease control rate.

Table 3 Comparison of adverse reactions between the two groups

Index	Study group (n = 45)		Control group (n = 45)		χ2	P value
	n	%	n	%
Abnormal liver function	1	2.22	5	11.11
Nausea and vomiting	3	6.67	6	13.33
Diarrhoea	2	4.44	3	6.67
Decreased white blood cells	1	2.22	2	4.44
Total	7	15.56	16	35.56	10.512	< 0.001